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Abstract
Pleiotropic effects of leptin have been identified in reproduction and pregnancy, particularly in the placenta, where it works
as an autocrine hormone. In this work, we demonstrated that human chorionic gonadotropin (hCG) added to JEG-3 cell line
or to placental explants induces endogenous leptin expression. We also found that hCG increased cAMP intracellular levels
in BeWo cells in a dose-dependent manner, stimulated cAMP response element (CRE) activity and the cotransfection with an
expression plasmid of a dominant negative mutant of CREB caused a significant inhibition of hCG stimulation of leptin
promoter activity. These results demonstrate that hCG indeed activates cAMP/PKA pathway, and that this pathway is
involved in leptin expression. Nevertheless, we found leptin induction by hCG is dependent on cAMP levels. Treatment with
(Bu)2cAMP in combination with low and non stimulatory hCG concentrations led to an increase in leptin expression,
whereas stimulatory concentrations showed the opposite effect. We found that specific PKA inhibition by H89 caused a
significant increase of hCG leptin induction, suggesting that probably high cAMP levels might inhibit hCG effect. It was
found that hCG enhancement of leptin mRNA expression involved the MAPK pathway. In this work, we demonstrated that
hCG leptin induction through the MAPK signaling pathway is inhibited by PKA. We observed that ERK1/2 phosphorylation
increased when hCG treatment was combined with H89. In view of these results, the involvement of the alternative cAMP/
Epac signaling pathway was studied. We observed that a cAMP analogue that specifically activates Epac (CPT-OMe)
stimulated leptin expression by hCG. In addition, the overexpression of Epac and Rap1 proteins increased leptin promoter
activity and enhanced hCG. In conclusion, we provide evidence suggesting that hCG induction of leptin gene expression in
placenta is mediated not only by activation of the MAPK signaling pathway but also by the alternative cAMP/Epac signaling
pathway.
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Introduction
The major role of the placenta is to establish a crosstalk between
maternal and fetal circulations. In addition, the placenta works as
an endocrine tissue that produces steroids, peptide hormones,
growth factors and cytokines that are crucial for the establishment
and maintenance of pregnancy. Several cytokines and growth
factors, such as leptin, are known to influence trophoblast
migration, proliferation and invasion [1].
Leptin, the product of the LEP gene, is a small non-glycosylated
pleiotropic peptide of 146 aminoacid residues (16 kDa), firstly
found to be secreted by adipose tissue [2], with the function of
modulation of satiety and energy homeostasis [3]. Compelling
evidence also implicated leptin in reproductive functions such as
the regulation of fertility, ovarian function, oocyte maturation,
embryo development and implantation [4,5,6]. The synthesis and
secretion of leptin as well as its functional receptors by trophoblast
cells have been widely demonstrated [7,8], suggesting that leptin
may act through a paracrine or autocrine mechanism. In this way,
previous studies have demonstrated the interactions between leptin
and some placental hormones, implicating leptin as a modulator of
placental endocrine function [9]. Moreover, leptin stimulates the
process of proliferation and protein synthesis, and inhibits
apoptosis [10,11,12,13] in human trophoblastic cells.
Deregulation of leptin metabolism and/or leptin function in the
placenta may be implicated in the pathogenesis of various
disorders during pregnancy, such as recurrent miscarriage,
gestational diabetes, intrauterine growth restriction, and pre-
eclampsia [14,15].
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Placental leptin production is strictly regulated and there are
differences between the regulation of transcription of human
placental and adipose leptin [16]. In fact, the human leptin gene
has an enhancer located at 21.9 kb that is activated by a
placental-specific transcription factor [17]. In this context, we have
previously reported that human chorionic gonadotropin (hCG), a
key hormone in pregnancy, upregulates placental leptin [18].
HCG mediates its action through the LH/hCG receptor, and
its major function is to maintain the progesterone production of
corpus luteum during early pregnancy. Binding of hCG to its
receptor generates, in the classical response, an increase in cyclic
adenosine monophosphate (cAMP) concentration and a conse-
quent activation of protein kinase A (PKA) (29). We previously
observed that (Bu)2cAMP not only did not enhance hCG effect but
also inhibited hCG dependent leptin expression in placental cells
[18]. The LH/hCG receptor has also been shown to mediate
activation of the mitogen-activated protein kinase (MAPK) (56,
57), Janus kinase and PI3K signaling pathways (58). Certainly, we
demonstrated that hCG treatment specifically activates MEK and
extracellular signal-regulated kinase 1/2 (ERK1/2) phosphoryla-
tion in placental cells and that this signal transduction pathway is
involved in hCG leptin up-regulation [18].
On the other hand, in a previous work we reported that the
expression of placental leptin is also regulated by cAMP [19].
Increases in intracellular cAMP classically lead to the activation of
PKA, which phosphorylates intracellular substrates, including the
cAMP response element binding protein (CREB) [20,21].
However, several reports have provided evidence that cAMP
affects some cellular processes independently of PKA [22,23,24].
Indeed, in that previous work, we demonstrated that leptin up-
regulation by cAMP involves a crosstalk between PKA and MAPK
signaling pathways [19]. It was also shown that hCG enhanced
leptin expression in placental cells involving a crosstalk between
cAMP and p38 pathways [25]. In many cellular activities cAMP
signaling has others mediators besides PKA, including cyclic
nucleotide-gated ion channels, and exchange protein directly
activated by cAMP (Epac) [26]. Interestingly, the two Epac1 and
Epac2 isoforms were identified as cAMP-binding proteins with
guanine nucleotide exchange factor (GEF) activities for the small
GTPases, Rap1 and Rap2 [27]. Upon cAMP binding, Epac
proteins undergo a conformational change, which relieves the
autoinhibition and then activates Rap proteins to regulate
numerous cellular actions [28].
It was demonstrated that the cAMP pathway can regulate ERK
signaling through several distinct mechanisms providing important
crosstalk between hormones and growth factor signaling. A model
that explains the activation of ERK by cAMP includes the
involvement of either Rap1 or Ras, and might include PKA
independent actions of cAMP [29].
The role of Epacs in Rap1 activation has been supported by
studies using 8-CPT-2Me-cAMP, a cAMP analogue that retains a
high affinity for Epac but does not activate PKA [30]. Epac-
mediated cAMP signaling is involved in cellular functions such as
cell differentiation, secretion/exocytosis, cell adhesion and cell–cell
junctions [31].
It was seen that in first and second trimester placenta, both
Epac1 and Epac2 were expressed in villous syncytiotrophoblast
(STB), cytotrophoblast (CTB), stroma, blood vessels and extra-
villous trophoblast (EVT). In term placenta, Epac1 and Epac2
were mainly distributed in the STB layer, EVT and blood vessels.
Interestingly, Epac1 and Epac2 were localized at the plasma
membrane and in the cytoplasm of BeWo cells, respectively [32].
The physiological significance of Epac expression on trophoblast
function is not completely known. In the last few years, the Epac
signaling pathway was associated with the cAMP-mediated
functional differentiation and syncytialization of human tropho-
blasts [32].
Since hCG and cAMP play a critical role in the control of
numerous placental hormones and seem to mediate leptin gene
expression in placenta, and given that multiple effectors can be
involved in the transduction of cAMP signaling, we reasoned that
leptin expression may be regulated through different effectors of
the cAMP signaling cascade. In the present work, we hypothesized
that placental leptin, as a key molecule of the implantation and
pregnancy, is finely regulated by hCG, a central hormone in
pregnancy, and that this regulation depends on a delicate balance
between MAPK and Epac/cAMP signaling pathways. Thus, we
aimed to investigate the mechanisms governing the regulation of
leptin expression by hCG and cAMP in human placenta and to
unravel the signaling pathways involved.
Our study demonstrates that hCG induces leptin expression in
placenta through the MAPK pathway and cAMP stimulation. At
the same time, the role of cAMP as a second messenger of hCG
would be PKA independent and involves the activation of the
alternative cAMP/Epac pathway.
Materials and Methods
Ethics Statement
Written informed consent was obtained from all subjects and all
study procedures were approved by ethical review committees at
the Virgen Macarena University Hospital and the Alejandro
Posadas National Hospital (Bioethics Comitte ‘‘Dr. Vicente
Federico del Giudice’’).
Cell Culture and Treatments
The human choriocarcinoma cell lines BeWo and JEG-3 were
purchased from the American Type Culture Collection (ATCC,
Rockville, MD). Cells were grown in DMEM-F12 (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS),
100 U/ml penicillin, 100mg/ml, streptomycin, 2 mM glutamine
(Invitrogen), and 1 mM sodium pyruvate (Sigma Chemical Co.,
St. Louis, MO) at 37 C in 5% CO2. To test the effect of cAMP,
the cAMP analogue dibutyryl cAMP [(Bu)2cAMP] (1 mM to
1 mM) (Sigma Chemical Co.) was used to facilitate cell entrance.
The effect of recombinant hCG (Sigma Chemical Company, St.
Louis, MO) was tested at different doses (5 IU hCG/ml to 100 IU
hCG/ml). In experiments designed to analyze the signal trans-
duction pathways involved in hCG stimulation of leptin, the cell-
permeable adenylyl cyclase inhibitor SQ22,536 (100 mM), the
selective inhibitor of cAMP-dependent protein kinase (PKA) H89
(10 mM), the MAPK kinase (MEK) inhibitor PD98059 (50 mM)
and the selective cAMP analogue that stimulates Epac, 8CPT-
2me-cAMP (10 mM) (Sigma Chemical Co.) were used. Inhibitors
were added 30 min before hCG or cAMP analogues treatment,
except in experiments performed to determine protein phosphor-
ylation, in which the inhibitors were added 10 min before
treatments. All treatments were performed in DMEM-F12 media
supplemented with 1% FBS unless indicated. Serum present in the
media of incubation was reduced from 10 to 1% to lower
nonspecific effects.
Placental Explants Collection and Processing
Human placentas (n = 9) were obtained after cesarean section or
vaginal delivery after normal term pregnancies and immediately
suspended in ice-cold PBS and transported to the laboratory,
where they were washed two to three times in sterile PBS to
remove excess blood. Villous tissue free of visible infarct,
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calcification or hematoma was sampled from at least five
cotyledons at a distance midway between the chorionic and basal
plates. These core parts of cotyledons were cut into multiple cubic
segments (10 to 15 mg wet weight) and thoroughly rinsed with
cold Hanks’ medium pH 7.4 (137 mM NaCl, 5 mM KCl,
1 mM CaCl2, 1 mM MgSO4, 0.3 mM Na2HPO4,
0.4 mM KH2PO4, and 4 mM NaHCO3). None of the donor
patients suffered from anomalous pregnancy. This study was
approved by the patient’s written consent and by the local ethical
committee.
Treatments of Placental Explants
Placental explants were randomly distributed in tubes contain-
ing 1 ml of DMEM-F12 medium (n = 1 explant/tube, four
replicates per treatment). Placental explants were maintained in
a shaking water bath at 37uC during 5 min to equilibrate
temperature, pre-incubated during 30 min when indicated with
50 mM PD98059, 10 mM H89 and incubated in the same medium
supplemented or not with hCG (100 IU/ml) and/or 10 mM Cpt-
O-Me or 10 mM (Bu)2cAMP during 4 h for leptin expression
analysis and 15 min for phosphorylation experiments. Explants
were removed from the bath, centrifuged for 2 min at 2000 g at
4uC and resuspended in 500 ml of lysis buffer (16PBS, 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate (SDS), and 10 mg/ml phenylmethanesulfonyl fluoride
(PMSF)) during 30 min at 4uC on an orbital shaker and later
centrifuged at 10000 g for 20 min. Supernatants were analyzed by
Western blot.
For real-time PCR, after thoroughly washing with phosphate
buffer saline, the tissues were immediately frozen at 80uC and
stored until extraction of total RNA.
Western Blot Analysis
Cells were seeded at 50–60% confluence in DMEM-F12
medium supplemented with 10% FBS. Each treatment was
performed in the same media supplemented with 1% FBS during
3 days for leptin immunoblot or during 10 min for protein
phosphorylation determinations. Total cell lysates were prepared
in lysis buffer. The lysates were centrifuged at 10,000 g for 10 min
to remove cellular debris. The protein concentration of the
supernatant was determined by the Bradford staining method
[33], with BSA as standard. Lysates were mixed with Laemmli’s
sample buffer containing 2% sodium dodecyl sulfate and 30 mM
b-mercaptoethanol, boiled for 5 min, resolved by SDS-PAGE on a
12% gel, and electrophoretically transferred to a nitrocellulose
membrane (Hybond; Amersham Pharmacia Biotech, Piscataway,
NJ) thereafter. Membranes were equilibrated in 1X PBS, and
nonspecific binding sites were blocked by 5% nonfat milk in PBS
at room temperature for 1 h. The membranes were then
immunoblotted with polyclonal rabbit antihuman leptin Y20
(1:1000) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or with
polyclonal rabbit antiphospho-ERK 1/2 (Thr202/Tyr204)
(1:3000) (New England Biolabs). Loading controls were performed
by immunoblotting the same membranes with polyclonal rabbit
anti-b-actin (1:5000) (Sigma Chemical Co.), or with polyclonal
rabbit anti total-ERK 1/2 (1:3000). The antibodies were detected
using horseradish peroxidase-linked goat anti-rabbit IgG (1:10000)
(Santa Cruz Biotechnology, Inc.) and visualized by the Amersham
Pharmacia enhanced chemiluminescence signaling system and a
Bio-Imaging Analyzer Fujifilm LAS-1000 (Fuji Photo Film Co.,
Ltd., Tokyo, Japan). Quantification of protein bands was
determined by densitometry using Image J ink 1.45 program
(National Institute of Health, Bethesda, MD, USA).
Plasmids
The luciferase (Luc) reporter constructs are based on pGL-3
basic vector. They were all kindly provided by Oksana Gavrilova
[17]. pRSV-b-gal contains the b-galactosidase gene under the
control of the Rous sarcoma virus (RSV) promoter and was used
to normalize the efficiency of individual transfections. pMtC-a is a
5.4-kb expression vector plasmid containing the cDNA for the a
isoform of the mouse cAMP-dependent protein kinase (PKA)
catalytic subunit [34]. pMt-REV is a 7.6-kb expression vector that
contains a dominant negative mutant cDNA of the mouse PKA
regulatory I-subunit (PKI) inserted between the mouse metallo-
thionein-promoter and the polyadenylation signal sequence of the
human GH gene [35].
Plasmids pMT2-HA-Rap1A contained the coding sequence for
murine Rap1A [36]; pMT2-HA-Epac, pMT2-HA-Rap1GAP and
expression vector for negative mutant of CREB, pCREBM1, were
a generous gift of Dr O. Coso (Department of Physiology and
Molecular Biology, FCEN, UBA, Buenos Aires, Argentina).
Plasmid CREBM1 contains a conservative serine-to-alanine
substitution at position 133 that destroys the PKA phosphorylation
site [37]. Plasmid pGL3-CRE-Luc containing the CRE element
cloned next to the luciferase gene was kindly provided by Adalı´
Pecci (Department of Biological Chemistry, FCEN, UBA, Buenos
Aires, Argentina).
In experiments using expression plasmids, the empty vectors
were used as controls. To perform transient transfection assays,
plasmids were purified using the Maxipreps Wizard kit (Promega
Corp., Madison, WI), and the concentration of DNA was
estimated spectrophotometrically.
Transient Transfection Experiments
For transient transfection experiments, BeWo cells were plated
at a density of 2.56105 cells/ml onto six-well dishes containing
2 ml of DMEM-F12 plus 10% FBS. Cells were incubated for 24 h.
Medium was replaced, and transfection of cells was performed
according to the standard liposome-mediated method. To
determine the sensitivity of the method in this cell type, a standard
dose of reporter plasmid vs. light emission was performed (data not
shown). Typically, 5 mg of the Luc reporter and 5 mg of pRSVb-
gal internal control construct were transfected using 5 ml of
LipofectAMINE (Life Technologies, Inc., Gaithersburg, MD). The
medium was replaced after 5 h with DMEM-F12 1% FBS with
the addition of the different effectors. Transfection analysis was
performed by duplicate in each of at least three independent
experiments.
Assays for Luc and b-galactosidase Activities
Luc activity in cell lysates was measured using the Luc Assay
System (Promega Corp.). Cells were washed with PBS and
harvested 72 h after transfection using 50 ml of lysis buffer. Cell
extracts were centrifuged and 30 ml of the supernatant was mixed
with 50 ml of Luc assay buffer. Luc activity was measured with the
GloMax-Multi+ Microplate Multimode Reader luminometer
(Promega Corp). b-Galactosidase activity was assayed using
1 mg of onitrophenyl-D-galactopyranoside (AmResco, Solon,
OH) as the substrate in buffer Z (60 mM Na2HPO4,
40 mM NaH2PO4,10 mM KCl, 1 mM MgSO4, and 0.07% b-
mercaptoethanol) and incubated at 37uC until yellow staining.
The product was determined by absorption at 420 nm. This value
was used to correct variations in transfection efficiency. Luc results
were calculated as the ratio of Luc activity per unit of b-
galactosidase activity. Duplicate samples were analyzed for each
data point.
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Quantitative Real-Time RT-PCR (qRT-PCR) Assay
Abundance of leptin mRNA was determined by qRT-PCR.
Total RNA was extracted from JEG-3 or placental explants using
TRISURE reagent, according to the manufactures instructions
(Bioline Co., Essex, UK). Concentration and purity of the isolated
RNA were estimated spectrophotometrically at 260 and 280 nm.
For cDNA synthesis, 5 mg of total RNA was reverse transcribed at
50uC during 1 h using the Transcriptor first Strand cDNA
synthesis Kit (Roche, Indianapolis, IN). Quantitative real- time
PCR was performed using the following primers based on the
sequences of the National Center for Biotechnology Information
GenBank database: leptin: forward, 59GAACCCTGT-
GATTCTT39; reverse, 59CCAGGTCGTTATTTGG39; and
cyclophilin: forward, 59CTTCCCCGATACTTCA 39; rever-
se,59TCTTGGTGCTACCTC39. Quantitative RT-PCR Master
Mix Reagent kit was obtained from Roche (Fast Start universal
SYBR Green), and PCRs were performed on a Chromo 4 DNA
Engine (Bio-Rad, Hercules, CA). A typical reaction contained
10 mM of forward and reverse primer, 3 ml of cDNA, and the final
reaction volume was 25 ml. The reaction was initiated by
preheating at 50uC for 2 min, followed by heating at 95uC for
10 min. Subsequently, 41 amplification cycles were carried out as
follows: denaturation 15 sec at 95uC and 1 min annealing and
extension at 58uC. The threshold cycle (CT) from each well was
determined by the Opticon Monitor 3.1.32 Program (BioRad
Laboratories Inc). Relative quantification was calculated using the
22DDCT method [38]. For the treated samples, evaluation of
22DDCT indicates the fold change in gene expression, normalized
to a housekeeping gene (cyclophilin), and relative to the untreated
control. Melting curve analysis was performed to confirm
specificity of amplification. Reaction mixtures without reverse
transcriptase or RNA were run in parallel to ensure the absence of
sample contamination.
Intracellular cAMP Determination
BeWo cells were incubated in sterile 96-well plate with a seeding
density of 10000 cells per well. Cells were cultured in DMEM-F12
10% FBS during 24 h. Medium was replaced by DMEM-F12 1%
SFB and cells were treated with hCG (0–500 IU/ml) for 72 h.
Then, cAMP-Glo assay kit was used according to manufacturer’s
instruction (Promega Corp.). Luminescence was measured using
the GloMax-Multi+ Microplate Multimode Reader luminometer
(Promega Corp).
Data Analysis
For Western blots analysis, representative images of at least
three independent experiments are shown along with quantifica-
tion of immunoreactive bands. Quantitative RT-PCR experiments
were repeated separately at least three times to ensure reproduc-
ible results. Transient transfection experiments were repeated at
least three times and each treatment performed by duplicates.
Results are expressed as the meanSD. The statistical significance
was assessed by ANOVA followed by Bonferroni’s multiple
comparison post hoc test and was calculated using the GraphPad
Instat computer program (GraphPad, San Diego, CA). A P value
less than 0.05 was considered statistically significant.
Results
HCG Stimulates Leptin Expression and Increases cAMP
Levels in placenta
The choriocarcinoma cell lines BeWo and JEG-3 were used as
models for trophoblastic cells as previously reported [7,39].
Previous results have demonstrated that leptin and leptin receptor
are expressed in these cell lines, suggesting that leptin is probably
exerting both paracrine and autocrine effects [11]. We have
previously shown that hCG and cAMP stimulate leptin expression
in BeWo and JEG-3 cells, as well as in placental explants [18,19].
In this regard, we aimed to demonstrate that hCG stimulates
leptin expression not only at the protein but also at the mRNA
level. Figure 1A shows that hCG (25–100 IU/ml) enhanced leptin
mRNA expression in JEG-3 cells, measured by qRT-PCR.
Maximal effect was achieved at 50 IU/ml, reaching a 11,7-fold
increase. The same effect was observed in placental explants
(Fig. 1B), where hCG significantly stimulated leptin mRNA
expression, reaching a 14,5-fold maximal increase at 100 IU/ml.
These results reinforce the notion that hCG has a role in
regulating leptin expression. On the other hand, we have
previously observed that treatment of trophoblastic cells with
(Bu)2cAMP causes a complete loss of hCG leptin induction [18].
For this reason, we aimed to determine if hCG could enhance
cAMP levels in the placenta. As seen in Fig. 1C, treatment with
hCG caused an increase in cAMP levels in BeWo cells, in a dose
dependent manner. Maximal effect was achieved at 500 IU/ml
hCG, a dose that elevated intracellular cAMP concentration to
3,8 mM. To further confirm activation of the cAMP pathway by
hCG, we performed a transient transfection assay with a vector
containing tandem CRE elements fused to the Luc reporter gene
(pCRE-Luc). BeWo cells were treated with hCG (50 or 100 IU/
ml), 1 mM (Bu)2cAMP or cotransfected with the expression
plasmid for the transcription factor CREB. Results are shown in
Fig. 1D. HCG stimulated CRE elements activity, reaching a 1,72-
fold induction with 100 IU/ml of hCG. This stimulation was even
higher than the stimulation caused by cAMP or by cotransfection
with CREB. To establish a link between hCG and CREB
transactivation on the leptin promoter, we performed a cotrans-
fection with pL1951 and an expression plasmid for a mutant
CREB (CREBM1), containing a conservative serine-to-alanine
substitution at position 133 that destroys the PKA phosphorylation
site. Results in Figure 1E show that CREBM1 was completely
unable to activate transcription of leptin promoter both in the
presence or absence of hCG. Cotransfection with CREBM1
caused a significant inhibition of hCG stimulation of leptin
promoter activity, with a 112-fold reduction compared with hCG
treatment. Taken together, these results demonstrate that hCG is
able to increase cAMP levels in trophoblastic cells and this effect
probably leads not only to activation of CREB protein but also to
the stimulation of the transcription of different genes trough CRE
elements.
High cAMP Levels Interfere with hCG Stimulation of
Leptin Expression
Previous data have shown that treatment with hCG (50 or
100 IU/ml) in combination with (Bu)2cAMP causes a complete
loss of hCG induction of leptin expression in placental cells [18].
These results were observed both at the transcriptional and protein
levels. In order to measure cAMP effect on hCG enhanced leptin
mRNA expression, we performed quantitative RT-PCR in
placental explants. As expected, hCG and cAMP increased leptin
mRNA levels 64 and 66-fold respectively (Fig. 2A). When hCG
treatment was combined with cAMP, leptin mRNA expression
was inhibited 62-fold relative to hCG treatment.
Some authors have shown that hCG receptor can be positively
or negatively regulated depending on cAMP concentration and
time of exposure [40]. This evidence raises the possibility that the
observed inhibition of hCG leptin induction, may be due to high
intracellular cAMP levels generated by hCG treatment (Fig0 1C)
combined with exogenously added (Bu)2cAMP. In this context, we
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determined leptin expression by Western blot in BeWo cells
treated with low and non stimulatory hCG concentrations in
combination or not with (Bu)2cAMP. Under these experimental
conditions, cAMP treatment led to a significant increase in hCG
leptin induction (Fig. 2B). Maximal effect was achieved at 1 mM
(Bu)2cAMP with a 2,81-fold increase. As expected, treatment with
5 or 10 IU/ml hCG alone, had no effect on leptin expression.
Taken together, these results demonstrate that high cAMP
concentrations could lead to inhibition of the hCG stimulatory
effect.
The hCG Stimulatory Effect on Leptin Expression is
Blocked by PKA Activation
PKA activation is the classical pathway activated by cAMP
when the levels of this nucleotide rise [41]. Therefore, we next
investigated the involvement of PKA on leptin induction by hCG.
BeWo cells were treated with 100 IU/ml hCG in the presence or
absence of 10 mM H89, a specific PKA inhibitor. Leptin
expression was measured by Western blot analysis (Fig. 3A). As
previously seen, 100 IU/ml hCG produced a 2,32-fold induction
of leptin expression. This effect was even higher when cells were
pretreated with 10 mM H89, reaching a 2,87-fold induction over
control. We next decided to examine the effect of PKA activation
on hCG leptin induction at the transcriptional level. BeWo cells
were transiently transfected with pL1951 Luc reporter construct
and treated with hCG, H89 or SQ (a specific adenilyl cyclase
inhibitor), and/or cotransfected with the expression plasmid for
the catalytic subunit of PKA, as indicated. As displayed in Fig. 3B,
treatment with hCG significantly stimulated leptin promoter
activity and this effect was enhanced 2-fold upon combination
with H89. Moreover, hCG effect on leptin expression was
inhibited 8,7-fold when cells overexpressed the catalytic PKA
subunit. Treatment with SQ alone or in the presence of hCG
showed no effect on leptin expression. All together, these results
suggest that the PKA signaling pathway is not involved in the
mechanisms regulating hCG leptin induction. Furthermore, the
observed cAMP inhibition of hCG action on placental leptin could
be mediated by PKA activation.
Figure 1. hCG stimulates leptin mRNA expression and enhances cAMP levels in placenta. (A) JEG-3 cells (16106 cells) were plated in
complete DMEM-F12 media supplemented with 1% FBS and incubated during 3 days with different doses of hCG (IU/ml). (B) Placental explants were
obtained as indicated in Materials and Methods and treated with increasing hCG concentrations. In (A) and (B), total RNA was extracted as described
in Material and Methods. Leptin mRNA was quantified by real time RT-PCR. Cyclophilin was used as internal standard. (C) BeWo cells (16105) were
seeded in 96-well plate and treated during 24 h with increasing concentrations of hCG, as indicated. cAMP-Glo assay kit was used to measure
intracellular cAMP concentration. (D) Cells were transiently transfected with pCre-Luc plasmid construction and treated with hCG, (Bu)2cAMP or
cotransfected with CREB, as indicated, during 72 h in DMEM-F12 media supplemented with 1% FBS. Luciferase activity was measured in cellular
extracts and normalized to b-galactosidase activity. Activity obtained with empty vector (PGL-3 basic vector) was set as a control. (E) BeWo cells were
transiently transfected with pL1951 and treated with 100 IU/ml hCG and/or cotransfected with CREBM plasmid. Cells were incubated during 72 h in
DMEM-F12 1% FBS media. Luciferase activity was measured in cellular extracts and normalized to b-galactosidase activity. Activity obtained with
empty vector (PGL-3 basic vector) was set as a control. Results shown are from a representative experiment and are expressed as means 6 S.E.M. for
three independent experiments performed in duplicates. *p,0.05, **p,0.01, ***p,0.001 vs control; ###p,0.001 vs hCG treatment.
doi:10.1371/journal.pone.0046216.g001
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PKA Inhibits the hCG Activation of MAPK Signaling
Pathway
We have previously demonstrated that hCG stimulates the
MAPK/ERK signaling transduction pathway in placental cells
[18]. Other authors have also reported such ability of LH/hCG
receptor in different tissues [42,43,44]. In this way, we aimed to
investigate the effect of MAPK inhibition on leptin mRNA
expression in trophoblastic cells. JEG-3 cells were treated with
hCG or/and PD98059, a pharmacologic inhibitor that blocks
MEK’s ability to activate ERKs. Leptin mRNA was measured by
qRT-PCR. Results shown in Fig.4A confirmed that hCG
significantly stimulated leptin mRNA and that cotreatment with
MEK inhibitor completely blocked this induction. Based on these
results, we hypothesized that cAMP inhibition of hCG effect on
leptin expression could be partially due to the impairment of
MAPK signaling pathway by PKA.
Figure 2. cAMP induces leptin stimulation by hCG at low hormone concentrations. (A) Placental explants were processed as previously
described and treated with increasing hCG and/or (Bu)2cAMP concentrations during 4 h. Total RNA was extracted as described in Material and
Methods. Leptin mRNA was quantified with real time RT-PCR. Cyclophilin was used as internal standard. (B) BeWo cells (16106 cells) were plated in
complete DMEM-F12 media supplemented with 1% FBS and incubated during 3 days with different doses of hCG (IU/ml) and/or (Bu)2cAMP (mM), as
indicated. Cell extracts were prepared as indicated in Materials and Methods. Proteins were separated on SDS-PAGE gels and leptin expression was
determined by Western-blot. Molecular weights were estimated using standard protein markers. Loading controls were performed by
immunoblotting the same membranes with anti-b-actin. Bands densitometry is shown in lower panels. Molecular weight (kDa) is indicated at the
right of the blot. Representative results from three replicates are shown. **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0046216.g002
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To this end, we evaluated ERK activation in BeWo cells treated
with hCG in the presence or not of H89. ERK 1/2 phosphor-
ylation was assessed by Western blot. As seen in Fig. 4B, hCG
induced a 6-fold increase in ERK phosphorylation. When hCG
was combined with H89, the activation of ERK reached an 8-fold
increase compared to the control and a 4-fold induction above
hCG treatment. Moreover, when we treated placental explants
with hCG in combination with H89 and PD98059, we observed
an inhibition in hCG stimulation of leptin expression, measured by
real time PCR (Fig. 4C). Results shown in Fig. 4D demonstrates
that phosphorylation of ERK 1/2 is inhibited when placental
explants are treated with hCG plus H89 and PD98059. The effect
of MAPK inhibition prevails over the inhibition of PKA,
suggesting that the MAPK signaling pathway would be the main
pathway involved on the stimulatory effect of hCG on leptin
expression.
Taking together, these results demonstrate that hCG stimulates
the MAPK pathway and that cAMP/PKA pathway activation is
probably blocking this effect.
The Alternative cAMP/Epac Signaling Pathway is Involved
in Placental Leptin Induction by hCG
It was reported that cAMP can activate MAPK through
members of the Ras superfamily of proteins. In this mechanism,
cAMP binds to the guanidine exchange factor Epac and activates
Rap1, which then increases the phosphorylation of MAPK
[27,45]. Based on these evidences, we decided to study the role
of the cAMP/Epac alternative pathway on the hCG leptin
induction. We first determined whether the activation of the
cAMP/Epac pathway induces leptin expression in placental cells.
We performed cotransfection experiments with pL1951 plasmid
and expression plasmids for Rap1b and Epac proteins. Results are
shown in Fig. 5A. The overexpression of Rap1 alone, or both
Rap1 and Epac, produced a significant induction of leptin
promoter activity. In addition, we cotransfected cells with
pL1951 plasmid, Epac and RapGAP, a Rap1 GTPase-activating
protein which accelerates the ability of Rap1 to hydrolyze GTP
into GDP [46]. The overexpression of RapGAP protein caused a
significant inhibition of leptin promoter stimulation by Epac
(Fig. 5B).
We next investigated the involvement of the cAMP/Epac
pathway on the hCG dependent leptin induction. First, we
analyzed the effects of the general cAMP analogue (Bu)2cAMP
and the Epac selective cAMP analogue 8-(4-chloro-phenylthio)-2-
Omethyladenosine-39, 59-cyclic monophosphate (8-CPT-2Me-
cAMP, also referred in the text and figures as CPT-OMe) [47],
on leptin upregulation by hCG. To this end, we treated BeWo
cells with hCG, (Bu)2cAMP and CPT-OMe and leptin expression
was assessed by Western blot. Fig. 5C shows that hCG as well as
CPT-OMe produced a significant increase in leptin expression,
with a 2-fold induction when compared to the control. Moreover,
when hCG was combined with CPT-OMe, such stimulation was
significantly higher than stimulation with hCG alone. On the
other hand, treatment with hCG and (Bu)2cAMP inhibited leptin
upregulation as previously seen. As shown in Fig. 5D, similar
results were observed in placental explants. These results suggest
that activation of the cAMP/Epac alternative signaling pathway,
and not the PKA pathway participates in hCG upregulation of
leptin. To confirm the observed results, we performed transient
transfection experiments with pL1951 plasmid. As shown in
Figure 3. PKA blocks hCG stimulation of leptin. (A) BeWo cells were incubated during 3 days with hCG and/or H89, as indicated. Extracts from
cells were prepared as previously described and loaded in a 12% SDS-PAGE. Leptin expression was determined by Western-blot. Loading controls
were performed by immunoblotting the same membranes with anti-b-actin. Bands densitometry is shown in lower panels. Molecular weight (kDa) is
indicated at the right of the blot. Representative results from three replicates are shown. (B) BeWo cells were transiently transfected with pL1951 and
treated with 100 IU/ml hCG, 10 mM H89 and/or 100 mM SQ, or cotransfected with a plasmid expressing the catalytic subunit of PKA (PKA) (1 mg/ml)
(C), or with a dominant negative mutant of the regulatory subunit of PKA (PKI) (1 mg/ml). Cells were incubated during 72 h in DMEM-F12 1% FBS
media. Luciferase activity was measured in cellular extracts and normalized to b-galactosidase activity. Activity obtained with empty vector (PGL-3
basic vector) was set as a control. Results are expressed as mean 6 S.E.M. for three independent experiments. *p,0.05, **p,0.01, ***p,0.001 vs.
control; #p,0.05, ###p,0.001 vs. hCG treatment.
doi:10.1371/journal.pone.0046216.g003
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Fig.5E, hCG treatment caused a significant induction in leptin
promoter activity. CPT-OMe produced a 4,5-fold increase in
leptin expression. When cells were treated with hCG in
combination with CPT-OMe, a 3-fold induction was observed.
In order to study the crosstalk between the PKA, cAMP/Epac
and MAPK pathways in leptin induction, BeWo cells were treated
with hCG, H89 and/or CPT-OMe. Leptin expression was
measured by Western blot (Fig. 5F). The cAMP analogue
produced a 3,4-fold induction of leptin expression compared with
control. This stimulation was enhanced when CPT-OMe was
combined with hCG, reaching a 8-fold induction above control in
accordance with previous results. In addition, CPT-OMe in
combination with H89 caused a 5-fold increase above CPT-OMe
treatment, suggesting that leptin expression involves the cAMP/
Epac signaling pathway independently of PKA activation. To
further investigate the involvement of this pathway in the hCG
effect on leptin expression, we performed transient cotransfection
experiments using the reporter pL1951 construction and the
expression plasmids for the proteins Epac and Rap1. BeWo cells
were treated or not with 50 IU/ml hCG. Results are shown in
Fig.5G. Cotransfection with Rap1 or with both Epac and Rap1
caused a 2,33 and 3-fold induction in leptin expression,
respectively. In addition, when cells were cotransfected with Epac
or Rap1 and treated with hCG, we observed a significant
stimulation of leptin promoter activity, reaching a 3-fold induction
over control in both cases. Overexpression of both Epac and Rap1
Figure 4. PKA inhibits ERK activation by hCG. (A) JEG-3 cells (16106 cells) were plated in complete DMEM-F12 media supplemented with 1%
FBS and incubated during 3 days with hCG (IU/ml) and/or PD98059. Total RNA was extracted as described in Material and Methods. Leptin mRNA was
quantified by real time RT-PCR. Cyclophilin was used as internal standard. Results are expressed as mean6 S.E.M. for three independent experiments
performed in triplicates. (B) BeWo cells were incubated for 15 min with hCG and/or H89 as indicated. Extracts from cells were prepared as previously
described and loaded in a 12% SDS-PAGE. ERK 1/2 phosphorylation was determined by Western blot. Total ERK 1/2 protein level in extracts was
determined as loading control. Molecular weights were estimated using standard protein markers. Bands densitometry is shown in lower panel.
Results shown are from a representative experiment and are expressed as means 6 S.E.M. for three independent experiments **p,0.01 ***p,0.001
vs control; ###p,0.001 vs hCG treatment. (C) Placental explants were processed as previously described pre-incubated during 30 min with 50 mM
PD98059 and/or 10 mM H89 and treated with 100 IU/ml hCG during 4 h (C) or 15 min (D). (C) Total RNA was extracted as described in Material and
Methods. Leptin mRNA was quantified by real time RT-PCR. Cyclophilin was used as internal standard. (D) Extracts were prepared as previously
described and loaded in a 12% SDS-PAGE. ERK 1/2 phosphorylation was determined by Western blot. Total ERK 1/2 protein level in extracts was
determined as loading control. Molecular weights were estimated using standard protein markers. Bands densitometry is shown in lower panel.
doi:10.1371/journal.pone.0046216.g004
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plus hCG caused a significant 2,4-fold increase. When Epac or
Rap1 were overexpressed and cells were treated with hCG, the
stimulation was even higher than when treated with hCG alone.
Taken together, these data suggest that hCG induction of leptin
gene in placental cells is mediated not only by the MAPK signaling
pathway activation but also by the alternative cAMP/Epac
signaling pathway.
Discussion
Although little is known about the exact physiological role of
leptin during human pregnancy, recent observations suggest that
this hormone could be a key player in the regulation of embryo
implantation as well as in the maintenance of pregnancy. Leptin is
synthesized in the placenta [7] and pregnancy results in elevated
leptin levels [48]. Maternal plasma leptin levels decline to normal
values 24 h after delivery [49]. In normal pregnancy, plasma
leptin concentration was found to be in the range 7.4–19 ng/ml
[7]. Many physiological roles have been suggested for leptin in
human pregnancy such as regulation of placental function and
development, embryo implantation and growth
[14,15,50,51,52,53,54,55]. Little is known about the regulation
of leptin expression in placenta. In this way, it has been reported
that leptin synthesis is regulated by steroid hormones [56,57],
glucocorticoids and insulin [16]. It was also demonstrated that the
Figure 5. hCG induces leptin expression through the cAMP/Epac alternative signaling pathway. (A) BeWo cells were transiently
cotransfected with pL1951 and Epac (1 mg/ml) and/or Rap1b (1 mg/ml) proteins expression plasmids. (B) BeWo cells were transiently cotransfected
with pL1951 Epac (1 mg/ml) and/or RapGAP (1 mg/ml) proteins expression plasmids. (C) and (E) BeWo cells (16106 cells) were plated in complete
DMEM-F12 media supplemented with 1% FBS and incubated during 3 days with different doses of Cpt-OMe, hCG, (Bu)2cAMP, and H89, as indicated.
Cell extracts were prepared as indicated in Materials and Methods. Proteins were separated on SDS-PAGE gels and leptin expression was determined
by Western-blot. Molecular weights were estimated using standard protein markers. Loading controls were performed by immunoblotting the same
membranes with anti-b-actin. Bands densitometry is shown in lower panels. Molecular weight (kDa) is indicated at the right of the blot.
Representative results from three replicates are shown. (D) Cells were transfected with pL1951 plasmid construction and treated with hCG and/or
Cpt-OMe, as indicated. (F) BeWo cells were cotransfected with pL1951 and/or Epac and Rap1b and treated with hCG (IU/ml). In (A), (B), (D) and (F) cells
were incubated during 72 h in DMEM-F12 1% FBS media. Luciferase activity was measured in cellular extracts and normalized to b-galactosidase
activity. Activity obtained with empty vector (PGL-3 basic vector) was set as a control. Results are expressed as mean 6 S.E.M. for three independent
experiments. *p,0.05, **p,0.01, ***p,0.001 vs. control; #p,0.05, ##p,0.01, ###p,0.001 vs. hCG treatment. (G) Placental explants were
processed as previously described and treated with 100 IU/ml hCG and/or 10 mM Cpt-O-Me or 10 mM (Bu)2cAMP as indicated during 4 h. Proteins
were separated on SDS-PAGE gels and leptin expression was determined by Western-blot. Molecular weights were estimated using standard protein
markers. Loading controls were performed by immunoblotting the same membranes with anti-b-actin. Bands densitometry is shown in lower panels.
Molecular weight (kDa) is indicated at the right of the blot.
doi:10.1371/journal.pone.0046216.g005
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human leptin gene is actively engaged by hypoxia through
mechanisms that are common to other hypoxia-inducible genes
[58]. Moreover, we have previously shown that leptin expression
in placenta is upregulated by some important pregnancy signals
such as hCG, cAMP and estradiol [18,19,25,59]. In particular, in
the present work, we have studied the mechanisms involved in the
regulation of leptin expression by hCG in BeWo and JEG-3
human choriocarcinoma cells. These cells express both leptin and
its receptor [11]. They maintain many characteristics of human
trophoblast cells and have been widely used to study placental
cellular signaling [60,61,62]. Despite we used different cell lines,
both JEG-3 and BeWo, are extensively used for the study of
trophoblast function, and share many properties with villous
trophoblasts in terms of their morphology, biochemical markers
and hormone secretion [63]. The similarities between these lines
and trophoblast is of particular interest in view of the difficulty
involved in obtaining large amounts of freshly isolated trophoblast
cells and in succeeding in transfection procedures [64]. In spite of
similarities in several aspects, they differ in other characteristics,
such as their proliferative activity and degree of differentiation.
Thus, BeWo cells are less differentiated than JEG-3 cells, but they
have higher rates of proliferation [65]. Normal trophoblastic
explants from healthy donors were also studied to confirm the
physiological relevance of the results. The findings in this study
confirmed that hCG stimulates leptin expression in human
placenta. We observed that hCG was able to increase leptin
mRNA transcription not only in JEG-3 cells but also in term
placental explants. HCG has many important functions during the
course of pregnancy, including stimulation of progesterone
production, decidualization, angiogenesis and cytotrophoblast
differentiation [66,67,68]. HCG is already expressed in eight-cell
embryos and is secreted in high local concentrations by the
blastocyst entering the uterine cavity. Therefore, it is probably one
of the embryonic signals involved in the embryo-maternal dialogue
during the implantation window [69]. Binding of hCG to its
receptor generates signal transduction through activation of the
associated heterotrimeric G-proteins and, in the classical response,
there is an increase in cAMP and a consequent activation of PKA
[70,71]. In this way, here we have demonstrated that hCG
increases cAMP intracellular levels in placental cells. Our results
are in accordance with previous reports that observed that hCG
augments intracellular cAMP in placenta [72,73]. In addition, we
have found that hCG can activate CRE element activity in
transient transfection experiments. The core of the CRE sequence
is found in a variety of regulatory elements of genes that are
activated by PKA. The main transcription factor that binds CREs
is CREB, which is activated principally by phosphorylation. We
have found that CREB is involved in leptin induction by hCG,
suggesting that hCG stimulation of leptin could be mediated by
the cAMP/PKA signaling pathway. However, there are many
Figure 6. The MAPK and the alternative cAMP/Epac signaling pathways participate in leptin stimulation by hCG in placenta.
Proposed model of the signaling pathways involved in hCG stimulation based on current data and its relation to leptin expression. Pointed arrow:
Stimulation; Flat arrow: Inhibition. Dash arrow: possible pathways involved.
doi:10.1371/journal.pone.0046216.g006
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other signaling pathways that activate CREB. Several studies have
reported that different kinases are able to phosphorylate and
activate CREB [74]. In fact, we found that (Bu)2cAMP not only
did not enhance hCG effect but even inhibited hCG-dependent
leptin mRNA expression in placental cells. It was recently
described that treating rats with hCG or chronically raising cAMP
production, downregulate LH/CG receptor. High concentrations
of hCG or cAMP negatively regulate surface receptors in ovary
and testis cells, thus decreasing the abundance of all receptor
transcripts [71]. The end of signaling mediated by G protein-
coupled receptor due to an excess of ligand has been described
both in vivo and in vitro in different cell types [75,76]. Our results
suggest that could exist alternative signaling pathways activated by
hCG, that prevent the rapid desensitization of the receptor in the
presence of high ligand concentrations, as occurs during implan-
tation and pregnancy. Some authors have shown that hCG
receptor is up- or down-regulated depending on the cAMP
concentration used and the exposure time [40]. In this context, we
demonstrated that low cAMP concentrations (,1 mM) combined
with low hCG concentrations (,10 IU/ml), induce leptin
placental expression. These observations strongly suggest that a
rise in endogenous cAMP level interferes with hCG leptin
stimulation.
It is known that the PKA pathway plays a central role in
biological signaling of various hormones in the placenta, such as
epinephrine, prostanoids, and hCG [77]. When we treated cells
with H89, we observed that this PKA inhibitor enhanced hCG
stimulation of leptin expression. Moreover, we demonstrated that
this effect occurs at the transcriptional level. Based on this, we
hypothesized that PKA activation by high cAMP levels might be
responsible for the impairment of hCG effect. In fact, several
reports have provided evidence that cAMP affects some cellular
processes independently of PKA [22,23,24]. We have previously
demonstrated that hCG stimulates leptin placental expression, at
least in part, through the MAPK/ERK signaling pathway [18]. In
this study, we confirmed those results, demonstrating that the
inhibition of the MAPK signaling pathway (using MEK inhibitor,
PD98059) completely blocks hCG induction of leptin mRNA
expression. The LH/hCG receptor has been shown to mediate
activation of MAPK signaling pathway [42,43,44,78,79]. In view
of the obtained results, we hypothesized that cAMP inhibition of
hCG effect on leptin expression could be due not only to a
desensitization/down-regulation of LH/hCG receptor [71,80] but
also to an inhibition of MAPK signaling pathway generated by
PKA activation. Our results demonstrated that induced ERK
phosphorylation by hCG in trophoblastic cells is increased when
PKA is specifically inhibited with H89. Depending on the cell type
and culture conditions, the activation of PKA results in the
activation or the inhibition of ERK 1/2 pathway [81,82].
On the other hand, the activation of PKA is known to
counteract the Ras/Raf-1/MEK signaling pathway [83,84,85,86]
that is essential to trigger ERK phosphorylation. Cyclic AMP,
however, seemingly promotes ERK activity in several cell types,
including 3T3- preadipocytes, ovarian granulosa cells, melanoma,
pituitary cells, and neuronal cells [27,28].
As we have demonstrated that hCG increases cAMP levels in
placental cells, we studied the possibility that an alternative cAMP
signaling pathway, independent of PKA, could be participating in
hCG leptin up-regulation. Given that hCG induces leptin
expression through the MAPK signaling pathway, we searched
for the pathway linking the cAMP signal to ERK activation.
Although the most important target of cAMP is PKA, recently, a
cAMP-guanine nucleotide exchange factor (cAMP-GEF)/Epac,
emerged as a Rap1-specific GEF [26,27], indicating that cAMP
can modulate ERKs via the Epac/Rap1/B-Raf pathway in a
PKA- and Ras-independent manner [27,28,87,88].
In the present work we have demonstrated that leptin
expression is induced in placenta through the cAMP/Epac
alternative signaling pathway by two different approaches. First
the overexpression of Epac and Rap1 proteins resulted in a
significant increase in leptin promoter activity. Furthermore, when
trophoblastic cells were treated with CPT-OMe, a cAMP
analogue that specifically activates Epac, an increase in leptin
expression was observed. Our results demonstrate that cAMP
stimulates placental leptin expression not only through the PKA
dependent pathway, as previously demonstrated [19], but also
through the cAMP/Epac alternative pathway. On the other hand,
since PKA might be responsible for cAMP inhibition of hCG effect
on leptin, we speculated that the cAMP/Epac alternative pathway
is involved in hCG leptin induction. We found that cAMP-
dependent activation of Epac1 and Rap1 but not PKA is able to
induce hCG leptin expression. Indeed, stimulation of Epac with
CPT-OMe caused an increase in hCG effect on leptin protein
expression and leptin promoter activity. It was previously reported
that besides to the inhibition of Ras-Raf-Mek cascade, PKA may
negatively regulate Rap1 itself [89], thus PKA may also inhibit
MAPK stimulation through the cAMP/Epac signaling pathway.
In cells expressing the Raf isoform B-Raf, cAMP is known to
activate ERK via the activation of Rap1 [87,90,91,92,93].
Furthermore, it was reported that B-Raf is expressed in
trophoblastic cells and ablation of B-Raf abrogated ERK
phosphorylation [94]. Even though MAPK activation by Epac/
Rap1/B-Raf is one possible pathway involved in leptin induction
by hCG, we do not discard the involvement of other signaling
pathways downstream of Rap1, independent of ERK signaling.
Although the physiological significance of Epac expression on
trophoblast function remains unknown, here we have shown that
Epac is an important player in the induction of leptin expression
by hCG. We have presented evidence indicating that hCG
stimulates leptin expression in placenta through a signal
transduction pathway including Epac, Rap1, and probably B-
Raf, up-stream of the MEK-ERK cascade. This pathway
integrates the cAMP signal to promote leptin expression in a
PKA independent manner. On the other hand, hCG could
stimulate leptin through MAPK signaling pathways involving the
Ras and Raf-1 proteins, in a cAMP independent manner.
Therefore, the activation of the MAPK and cAMP/Epac signaling
pathways underlie the stimulation of leptin expression by hCG. At
the same time, hCG is capable of activating the classical cAMP/
PKA pathway in placenta, but this pathway would not be involved
in the stimulation of leptin by hCG. In turn, cAMP generated by
the action of several effectors through the activation of PKA,
would stimulate leptin. All these interrelationships are pictured in
the model shown in Fig. 6.
In summary, although multiple pathways are required for leptin
stimulation by cAMP, only some of them are dependent on PKA,
while others, like pathways activated by hCG, would be
independent of PKA. Until now, no studies have addressed the
role of the cAMP/Epac in the regulation of leptin by hCG in
placenta. Based on our results we can speculate that the activation
of the cAMP/Epac signaling pathway would provide an alterna-
tive pathway to avoid the inhibition of leptin hCG stimulation
when PKA is activated, thus ensuring leptin expression require-
ments during pregnancy.
The molecular actions of leptin and mechanisms coordinating
its expression and activity in trophoblasts are not fully elucidated.
In this work we showed a novel mechanism activated by hCG in
placenta to induce leptin expression.
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